NEW YORK, November 10, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Vodafone Group Plc (NASDAQ: VOD), Zulily Inc. (NASDAQ: ZU), Starbucks Corporation (NASDAQ: SBUX), McKesson Corporation (NYSE: MCK) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7814-100free.
--
Vodafone Group Plc Research Reports
On November 6, 2014, Vodafone Group Plc (Vodafone) announced that Gartner's has recognized the Company as a leader in the first ever Magic Quadrant for Managed Machine-to-Machine (M2M) Services, for both ability to execute and completeness of vision. Vodafone's Director of M2M, Erik Brenneis said, "This is tremendous news for Vodafone and we feel it shows that we have a strong, successful and differentiated approach to M2M. This is a highly competitive market and we will use this recognition as a spur to ensure that we continue to innovate while maintaining a focus on delivering for our customers." The full research reports on Vodafone are available to download free of charge at:
http://www.analystsreview.com/Nov-10-2014/VOD/report.pdf
--
Zulily Inc. Research Reports
On November 4, 2014, Zulily Inc. (Zulily) released its Q3 FY 2014 and 9M FY 2014 financial results (period ended September 28, 2014). The Company reported a staggering 71.5% YoY improvement in its Q3 FY 2014 net sales to $285.8 million. Net loss attributable to Class A and Class B common stockholders came in at $0.8 million or $0.01 diluted loss share, compared to $4.8 million or $0.09 diluted loss per share in Q3 FY 2013. The Company's Q3 2014 non-GAAP diluted EPS stood at $0.02. Analysts polled by Thomson Reuters expected the Company to report Q3 FY 2014 adjusted loss per share of $0.03 on revenue of $285.28 million. For 9M FY 2014, the Company reported net sales of $808.7 million, up 84.4% YoY and net income attributable to Class A and Class B common stockholders came in at $4.0 million, compared to net loss of $7.5 million in 9M FY 2013. For Q4 2014, the Company expects net sales in the range of $391.3 million - $416.3 million, while full-year 2014 net sales is expected in the range of $1.20 billion - $1.225 billion. The full research reports on Zulily are available to download free of charge at:
http://www.analystsreview.com/Nov-10-2014/ZU/report.pdf
--
Starbucks Corporation Research Reports
On October 30, 2014, Starbucks Corporation (Starbucks) released Q4 FY 2014 and full-year FY 2014 earnings (period ended September 28, 2014). For Q4 FY 2014, net earnings attributable to Starbucks stood at $587.9 million or $0.77 per diluted share, compared to net loss of $1.2 billion or $1.64 diluted loss per diluted share in Q4 FY 2013. During the quarter, the Company's total net revenues improved 10.3% YoY to $4.18 billion, but trailed Thomson Reuters' consensus revenue forecast of $4.23 billion for the quarter. The Company's Q4 FY 2014 non-GAAP EPS came in at $0.74, in line with the average estimate of $0.74 per share for the quarter, compiled by Thomson Reuters. During full-year FY 2014, the Company's total net revenues improved 10.6% YoY to $16.4 billion, while net earnings attributable to Starbucks came in at $2.1 billion, compared $8.3 million in full-year FY 2013. The Company expects Q1 FY 2015 EPS between $1.20 and $1.28, while full-year FY 2015 revenue growth is expected in the range of 16% - 18% and EPS in the range of $3.42 - $3.54. The full research reports on Starbucks are available to download free of charge at:
http://www.analystsreview.com/Nov-10-2014/SBUX/report.pdf
--
McKesson Corporation Research Reports
On October 28, 2014, McKesson Corporation (McKesson) reported Q2 FY 2015 (period ended September 30, 2014) financial results. Revenues increased 35.7% YoY to $44.8 billion. Revenue from total Distribution Solutions increased 36.7% YoY to $44.0 billion, mainly driven by the contribution from the acquisition of Celesio and market growth. Net income attributable to McKesson came in at $469 million or $1.99 per diluted share, compared to $404 million or $1.74 per diluted share in Q2 FY 2014. The Company's Q2 FY 2015 adjusted diluted EPS from continuing operation stood at $2.79, surpassing average estimate of $2.73 per share compiled by Thomson Reuters. The Company's H1 FY 2015 (period ended September 30, 2014) revenues improved 36.2% YoY to $88.8 billion, while net income attributable to McKesson improved 5.3% YoY to $872 million. For full-year FY 2015, the Company expects adjusted diluted EPS from continuing operations in the range of $10.50 - $10.90. The full research reports on McKesson are available to download free of charge at:
http://www.analystsreview.com/Nov-10-2014/MCK/report.pdf
--
Thermo Fisher Scientific Inc. Research Reports
On November 4, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher) announced that its Senior Vice President and CFO, Peter M. Wilver is scheduled to present at the upcoming Baird's 2014 Industrial Conference on November 11, 2014, at 9:00 a.m. CST at the Four Seasons Hotel, Chicago, Illinois. The live webcast of the presentation will be available on the Investors section of Thermo Fisher's official website. The full research reports on Thermo Fisher are available to download free of charge at:
http://www.analystsreview.com/Nov-10-2014/TMO/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
